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Head and neck cancer is the collective name for cancers that arise in the head-neck (HN) region. 
These are tumors of the upper aerodigestive tract, of which oral cavity and larynx cancer are the most 
common, but head and neck cancer also includes tumors in the floor of the mouth, tongue, but also in 
the vermillion border of the lips, from the salivary glands, thyroid gland, tonsils and nasal cavity and of 
the soft tissues and bones in this area. The common cancers in the HN region mainly develop from the 
mucosa, resulting in head and neck squamous cell carcinomas (HNSCC). Other head-neck cancer types 
are adenocarcinomas, sarcoma’s, melanomas, squamous cell carcinomas of the skin and lymphomas 
that are more rare [1]. Complex skin cancers are often also treated in a multidisciplinary head and neck 
cancer center. The relative high frequency of HNSCC, compared to the other head and neck tumors, is 
because the epithelial layers of the oral cavity, pharynx and larynx are exposed to the same risk factors. 
The common risk factors are life style-related such as tobacco smoking especially when combined with 
alcohol use and dietary factors [2]. The continuous stress of the epithelial layers caused by exposure 
to tobacco smoke and alcohol causes wide-spread accumulation of genetic aberrations in the upper 
aerodigestive tract [3]. Other causes of HNSCC include viral infections of the Human papillomavirus in 
tonsillar carcinoma [4], the Epstein-Barr virus in nasal carcinoma or sunlight exposure in particular lip and 
skin cancers. 
 An important part HNSCC are those located in the oral cavity [5]. Worldwide, an estimated 300,400 new 
cases of cancer of the oral cavity, including lip and predominantly oral squamous cell carcinomas (OSCC) 
were diagnosed in 2012 and 145,400 deaths associated with these cancers in 2012 [5]. Furthermore, the 
incidence of these cancers has also been steadily increasing over the last few years. E.g. in 2012 in USA the 
estimated new cases of cancer in the oral cavity or pharynx (OPSCC) was 40,250 and 7,850 deaths [5]. In 
the 2016 these numbers had increased to 48,330 new cases and 9,570 deaths. Because, both the overall 
new cases of all cancers and all cancer-related deaths increased with 3% from 2012 to 2016, the increase of 
20% of new cases with OPSCC and 22% of deaths from 2012 to 2016 specifically, is highly significant [6], [7]. 
While the incidence of OSCC in the Netherlands is rather low, it has doubled over the last 25 years from 
507 cases in 1990 to 906 in 2015 (www.cijfersoverkanker.nl, visited on 02-03-2019). Meanwhile, the 5-year-
survival rate was 57% for OSCC diagnosed between 1991-1995 and only improved to a 62% 5-year survival 
for OSCC diagnosed between 2011-2015. Due to this stagnant 5-year survival combined with the increasing 
incidence, OSCC poses a big clinical challenge. 
The biological behavior of OSCC is local destruction of tissue, anatomy and organs and regional 
metastases to the lymph nodes in the neck. Distant metastasis of OSCC is rather rare at the moment of 
diagnosis and has been report to occur in 6-12% of patients [8]–[11]. When distant metastases do occur, it 
is in a late phase and are mostly located in the lungs.
The treatment modalities for locoregional treatment are primary surgery and occasionally primary 
radiotherapy for the low stages of OSCC. High stages OSCC require combined treatment with both 
surgery as well as postoperative radiotherapy. High stage carcinomas that cannot be surgically removed, 
are solely treated with radiotherapy. Progress is made in combining radiotherapy with systemic treatment 
like chemotherapy or with biologicals in high risk cases. All mentioned treatments have serious side 
540123-L-bw-Clausen




effects, so a tailormade treatment plan, based on expected behavior of the tumor is mandatory for good 
survival and quality of life.
A dilemma in the treatment of OSCC is the management of the “clinical negative neck”. This term refers to 
a common dilemma where there is no evidence for lymph node metastases based on clinical assessment 
and imaging, while due to tumor factors there is a substantial risk for the presence of microscopic 
metastases. The presence of lymph node metastasis was reported to reduce the five-year disease-free 
survival in patients with OSCC from 72 to 9% and had the highest hazard ratio of all reported clinical 
pathological predictors [12]. 
To assist in the detection of nodal spread in OSCC, specific clinicopathological traits that are associated 
with lymph node metastasis are included in risk assessment for LN metastasis. Certain tumor characteristics 
such as size, invasive behavior and the pattern of invasion are indicators of the tumor clinical behavior, 
and associated as well as predictive of lymph node metastasis [13]–[17]. Especially infiltration depth, 
perineural and lymphovascular invasion as well as histological differentiation have been found to be 
good clinicopathological predictors for cervical LN metastases in the neck [18]. These findings led to an 
important revision of the 8th edition of TNM staging guideline which includes now infiltration depth as 
part of the T-status in addition to conventional tumor diameter which was decisive in earlier version of 
the TNM staging [19], [20].
For patients with OSCC and a clinically negative neck (cN0) and a small tumor (T1-T2) [20], elective 
neck dissection is recommended [21]. In the past patients with cN0/T1-T2 were treated with a modified 
radical neck dissection, removing lymph node levels I to IV (Figure 1.1). Later these elective radical neck 
dissections were replaced by a “selective neck dissection” which removed a limited set of lymph nodes, 
level I to III (Figure 1.1). In about 70% of the cT1-T2/N0 OSCC cases, a neck dissection can be avoided with a 
“watchful waiting policy”, which refers to an intensive follow up regime. The avoidance of a neck dissection 
is especially relevant since this surgical procedure, even a selective neck dissection, is associated with 
complications such as loss of shoulder function, edema and increase of costs [22]. Additionally, for the 30% 
of the cN0 OSCC patients who suffer a conversion to a regional recurrence, the watchful waiting ensures 
a proper follow-up to diagnose and treat late occurring LN metastases as soon as possible [23], [24]. A 
recently development in N-status determination of OSCC is the Sentinel Lymph Node Biopsy (SLNB). To 
perform a SLNB, a radioactive tracer is injected around the primary tumor which can then visualize the 
lymphatic drainage pattern as well the primary draining sentinel lymph node from the tumor location with 
a SPECT scan. During surgery the sentinel lymph node can be detected with a probe and is removed for 
histological assessment. Additionally, after resection of the sentinel lymph node, micro metastases in this 
particular lymph node can be identified using immunohistochemistry. SNLB is an important contribution 
to the assessment of the neck in OSCC. The negative predictive value (NPV) of SLNB in OSCC for nodal 
spread has been reported to be between 88 to 95% [25], [26]. The SLNB has a lower sensitivity and NPV 
in floor of mouth tumors for detecting occult metastasis due to “shine through phenomenon”. This 
phenomenon is caused by the high proximity of the injection site of the tracer in the primary tumor and 
the lymph nodes in level I-A. As a result of the limited distance to the primary tumor, the high radioactivity 
of the site of tracer injection and the sentinel node cannot be properly distinguished [25], [27]. A drawback 
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of SLNB is the increased morbidity in case of a positive sentinel node [28], [29]. Patients with a positive 
sentinel lymph node are treated with a neck dissection were level I to V are removed. After a SLNB the 
neck dissection is more difficult due to residual wounds or scar tissue. Although SLNB is a good and less 
invasive procedure than an elective neck dissection, the current sensitivity of SLNB to detect occult 
metastases does not fully solve the dilemma in diagnosing nodal spread [30]. 
Until now only tumor infiltration depth is helpful in predicting micro metastases in the neck of OSCC. The 
statistical validity of other clinical predictors is often insufficiently tested and subjected to a high degree 
of observer-bias [32]–[35]. Nevertheless, these clinicopathological features are often used as the decisive 
factor in the treatment strategy [36]. Therefore, there is a need for another approach to solve the dilemma 
around the negative clinical neck. 
Molecular Tumor biomarkers predictive for N-status on Oral Squamous Cell Carcinomas
While great progress has been made in both the prediction of subclinical metastases in the neck of OSCC 
patients as well as treatment strategies, there is a group of tumors that behave differently and are not 
suited for staging and treatment with these methods. These are tumors with initially a low risk, but still 
develop later cervical metastases of an OSCC. Biomarkers may be helpful in selecting cases of OSCC 
that have a risk for subclinical metastases in the neck and need treatment for that. Molecular tumor 
biomarkers have been studied. These biomarkers are indicative of certain biological behaviors. These 






Figure 1.1. The six levels of lymph nodes in the lymphatic drainage patterns of OSCC tumors. Edited from [31] with permission.
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ability to metastasize to the lymph nodes. In the last decades, numerous molecular tumor markers have 
been identified and evaluated for association with LN status in OSCC (Table 1.1).
Table 1.1. Overview of single molecular biomarkers that have been shown to have aberrantly expressed proteins or 
mRNA levels in OSCC with LN metastases. 
Biomarker Alteration Major pathway associated with biomarker Reference
DF3/MUC1 Over expression Cell cycle regulation, proliferation, apoptosis. [37]
ALDH-1 Over expression Cell cycle regulation, proliferation, apoptosis. [38]
PTEN Under expression Cell cycle regulation, proliferation, apoptosis. [39]
Bcl2 Over expression Cell cycle regulation, proliferation, apoptosis. [39]
Shp2 Over expression Cell cycle regulation, proliferation, apoptosis. [40]
MT3 Under expression Cell cycle regulation, proliferation, apoptosis. [41]
PDL-1 Under expression Cell cycle regulation, proliferation, apoptosis. [42]
ATG16L1 Over expression Cell cycle regulation, proliferation, apoptosis. [43]
ABCB5 Over expression Cell motility, cell adhesion, microenvironment. [44]
Twist Over expression Cell motility, cell adhesion, microenvironment. [45]
E-cadherin Under expression Cell motility, cell adhesion, microenvironment. [46]
Podolopin Under expression Cell motility, cell adhesion, microenvironment. [46]
VEGF-C Over expression Cell motility, cell adhesion, microenvironment. [47]
ITGA3 Over expression Cell motility, cell adhesion, microenvironment. [48]
ITGB4 Over expression Cell motility, cell adhesion, microenvironment. [48]
Claudin-7 Under expression Cell motility, cell adhesion, microenvironment. [49]
DNp63 Under expression Cell motility, cell adhesion, microenvironment. [50]
MMP-11 Over expression Cell motility, cell adhesion, microenvironment. [51]
ANO1 Over expression Cell motility, cell adhesion, microenvironment. [52]
uPAR PAI-1 Under expression Cell motility, cell adhesion, microenvironment. [53]
S100A4 Over expression Cell motility, cell adhesion, microenvironment. [54]
COX-2 Over expression Cell motility, cell adhesion, microenvironment. [55]
CYFRA 21-1 Over expression Cell motility, cell adhesion, microenvironment. [56]
CD68+ TAMs Over expression Cell motility, cell adhesion, microenvironment. [57]
Claudin-1 Over expression Cell motility, cell adhesion, microenvironment. [58]
CMTM3 Over expression Cell motility, cell adhesion, microenvironment. [59]
E-cadherin Under expression Cell motility, cell adhesion, microenvironment. [60]
EPOR Over expression Transcription factors, immune system, angiogenesis. [61]
NKX3-1 Under expression Transcription factors, immune system, angiogenesis. [62]
NNMT Over expression Transcription factors, immune system, angiogenesis. [63]
CNTN1 Over expression Transcription factors, immune system, angiogenesis. [64]
KLK13 Under expression Transcription factors, immune system, angiogenesis. [65]
TANGO Over expression Transcription factors, immune system, angiogenesis. [66]
CD163 Over expression Transcription factors, immune system, angiogenesis. [67]
AEG-1 Over expression Transcription factors, immune system, angiogenesis. [68]
Lin28B Over expression Transcription factors, immune system, angiogenesis. [69]
CAIX Over expression Transcription factors, immune system, angiogenesis. [70]
GCS/P-gp Over expression Transcription factors, immune system, angiogenesis. [71]
IL-37 Under expression Transcription factors, immune system, angiogenesis. [72]
KiSS-1 Under expression Transcription factors, immune system, angiogenesis. [73]
miR-483-5p Under expression Transcription factors, immune system, angiogenesis. [74]
Indicated is also in what major pathway each of these markers have been reported to be involved in. Adapted from [75] with 
permission.
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Changes in proteins levels in HNSCC are often due to underlying genetic alterations such as differences 
in gene copy numbers. However, different studies using such protein markers are hard to compare due to 
high variability of different tumor characteristics, the variation in immune-staining methods and scoring 
systems used to determine protein levels, as well as the subjective interpretation of the observers when 
assessing the protein expression [76]. Without a golden standard to determine tumor characteristics it 
is very difficult to directly compare protein and RNA expression between biomarker studies. And so far, 
the poor predictive value of such markers did not result in the incorporation into clinical modalities yet 
[77]–[79]. 
Invasion and metastasis are complicated multistep processes that rely on the deregulation of many 
different genes and pathways. This might be a reason why it is difficult to identify a single aberrantly 
expressed protein in the primary tumor that is predictive for tumor metastases [80], [81]. Fortunately, 
technical advances and novel methods that allow the simultaneous assessment of a high number 
of genes, have greatly improved biomarker discovery. Moreover, this progress has allowed for more 
elaborate profiling of tumors, enabling stratification of tumors which have similar histology or staging 
but are vastly different on a genetic level [82]. In order to investigate whether a gene expression profile 
could be identified that is predictive for the presence of lymph node metastasis in HNSCC in 2005, 
Roepman et al. performed a microarray study in HNSCC [83]. The microarray analysis allowed for testing 
of 21,329 genes simultaneously which led to the assembly of a 102-gene expression profile associated 
with nodal spread in HNSCC with a negative predictive value of 86%. The gene-panel was subsequently 
further validated and expanded to a 696-gene expression profile which had a negative predictive value 
of 89% [78]. This extensive gene panel shows the possible variation in involved genes and the complexity 
of metastasis as a whole and but also the difficulty of identify a universal metastatic profile in HNSCC. 
Especially considering similar studies employing even larger microarrays identify markers report on the 
single gene BMI1 as mostly predictive for HNSCC metastasis [84] while this gene is not included in the 
696-gene expression profile reported [78]. And even this extensive study only covers genes, excluding 
emerging biomarkers like microRNA’s such as miR-21, miR-16 and miR-30a-5p that have been associated 
with nodal metastasis in HNSCC cell lines [85]. To summarize, even the microarray expression studies 
did not result in the incorporation of biomarkers into clinical modalities. Great variance has been seen in 
different gene signatures for HNSCC and the application of these panels might not be suitable for clinical 
application yet [82].
Epigenetics as regulators of gene expression
A relatively recently discovered biological mechanism of gene regulation is epigenetics (Figure 1.2). 
Epigenetics means “above genetics” and is a collective term for modifications of the DNA other than 
structural changes in the DNA sequence that do impact gene expression (reviewed in [86]). The 
phenomenon of epigenetics can be summarized as the “development of phenotypes from genotypes” 
as defined by Waddington in 1942 [87]. In general, epigenetics consists of modifications of the DNA 
structure. The DNA double helix is extensively folded and packaged in an array of structures to fit in a 
human nucleus. Each human diploid cell contains a total of about 2 meters of DNA [88]. To facilitate the 
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storage of DNA into a human diploid cell, DNA is extensively packed and folded to fit into a cell nucleus. 
The degree of packaging and the resulting structure is not uniform in the complete genome. The 
chromosomes, the largest DNA structures in the human cells, for example are known to have structures 
depending on the degree of packaging referred to as chromatin [89]. Each structural chromatin form 
has a different density of the structure and a corresponding rate of gene expression as a result of the 
physical availability of the chromatin for gene expression [90]. Euchromatin refers to the less packed 
DNA structure and is associated with an increased level of gene expression while heterochromatin is 
more densely packed and genes in this structure are relatively less expressed. On a lower structural level, 
DNA is wrapped around nucleosomes (Figure 1.2). These nucleosomes consist of building blocks called 
histones containing long protein tails. These additional amino acid tails can be further reversibly modified 
by the addition of molecules such as methyl groups and ubiquitin groups to alter the chromatin structure 
[90]. Additionally, the chromatin structure is modified by interaction with RNA such as long noncoding 
RNA [91], [92]. These different modifications result in different structures of the nucleosomes, resulting in 
different genomic regulation of the DNA bound to these structural proteins. It is general accepted that 
these various epigenetic mechanisms have major contribution to the regulation of gene expression [89], 
[90].Through the complex regulation of gene expression through chromatin modification, the same set 
of genes, or genotype, can accommodate vastly different life stages or phenotype. For example, within 
bees the genome of the Queen genotype and the worker genotype are complete identical while through 
epigenetic regulation the phenotypes are vastly different (Figure 1.3)[93]. 
Figure 1.2. Different levels of DNA structures impacting inheritable epigenetics. On the left, the largest DNA structure, the 
chromosomes are depicted. The density of the structure of the chromosomes impacts gene expression. Next, DNA strands are 
wrapped around larger proteins, the nucleosomes. These larger structural proteins contain proteins tails that can have different 
molecular modifications that impact the DNA structure that impact gene expression. Finally, molecular modifications of the 
nucleotides such as the addition of methyl groups change the DNA structure and impact gene expression as well. Adapted from [86] 
with permission.
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The smallest building blocks of DNA are the nucleotides adenine, guanine, thymine and cytosine. These 
bases can be methylated. The addition of a methyl group to single nucleotide can affect all four bases but 
highly favors cytosines that precede guanine residuals. These preferred sites of methylation are known 
as CG dinucleotides and often referred to as CpG sites (Figure 1.4). Because the Methyl molecule is always 
added to the 5’ position of a cytosine, a methylated cytosine molecule is referred to as 5’-methyl-cytosine 
or 5mC. DNA methylation affects the chromatin structure, contributing to gene expression regulation 
[89], [90], [94]. Additionally, a high percentage of nucleotide changes are caused by the spontaneous 
hydrolytic deamination of methylated cytosines which results in a thymine [95], [96]. 
DNA methylation contributes to DNA changes is several ways. Accumulation of DNA methylation in 
the promoter region of genes is often associated with gene expression downregulation [94], [97], [98]. 
Generally, DNA methylation can lead to transcriptional repression in three ways [98]. The added methyl 
groups are capable of physical blocking the binding of transcription factors to gene regulatory regions. 
Additionally, methylated cytosines can attract methyl-binding proteins such as the methyl CpG binding 
proteins (MECP-1 and MEPC-2) chaperoning all (de)regulatory transcription factors to sites with dense 
Figure 1.3. Schematic describing the influence epigenetic regulation by DNA methylation in phenotype development in 
honey bees. Each female egg begins in a totipotent state but develops different as a result of different DNA methylation caused by 
changes in nutrition. The differential methylation affects gene expression and gene splicing resulting in different growth, metabolism, 
and development that drive honey bee phenotype [93].
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CpG-islands [99]. Consequently, accumulation of DNA methylation can result in a more condensed 
structure of the chromatin [89]. 
DNA methylation can be enzymatically removed [101], therefore methylation status is a dynamic way of 
regulation of gene expression. However, DNA methylation is stable and does not reverse spontaneously. 
Consequently, DNA methylation status is copied during DNA replication, DNA methylation status is 
inheritable [102]. Even DNA released from their host cells retains any methylation of cytosines allowing for 
methylation detection in bodily fluids. CpG sites methylation status is maintained because CpG sites form 
genomic palindromes because cytosine and guanine nucleotides occur in base pairs, a CpG on either the 
forward or reverse strand of the DNA will have a reverse complimentary CpG on the other DNA strand. 
Since the methylation status of these CpGs is generally similar on both strands, DNA methylation status 
of these complimentary CpGs is transferred during cell division making DNA methylation inheritable to 
both daughter cells during mitosis [103]. About 1% of the human genome consists of CpG sites [104] of 
which 70 to 80% percent is methylated [105]. Additionally, these CpG sites are not evenly distributed [104]. 
Actually, the vast majority of the human DNA is void of CpG sites. The accumulation of CpG sites seems 
particularly high near gene regulatory regions that serve as important binding sites for the transcriptional 
complex near enhancers and Transcription Start Sites. Such CpG rich regions defined with a statistically 
significantly increased CpG density, are referred to as CpG islands [106]. 
DNA methylation levels are maintained by DNA Methylation Transferases (DNMTs) (Figure 1.5) [107]. 
There are three known DNMT proteins: DNMT1, DNMT3a and DNMT3b. DNMT1 maintains concordant 
DNA methylations status of opposite CpG sites on the different DNA strands. DNA methylation thus 
maintains tissue-specific DNA imprinting during cell-division [108], [109]. DNMT3a and DNMT3b facilitate 
the introduction of new DNA methylation of previously unmethylated CpG sites[107]. DNA methylation 
as a biomarker has several advantages compared to other tumor biomarkers such as mutations or RNA 
expression. The methylation status of a CpG sites can exist in only two states: methylated or unmethylated. 
In contrast, single nucleotide changes caused by mutations can change any base to any other base, 
creating a much larger amount of variability in outcome. In addition, changes of a single nucleotide do 
Figure 1.4. Schematic representation of the biochemical cytosine methylation and deamination of methylated cytosine to 
thymines. Adapted from [100] with permission.
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not necessarily lead to changes in the encoded protein since several nucleotide triplets can encode 
for the same amino acid. And a single amino acid change does not always lead to functional changes 
in the tertiary structure of a protein. The binary state of the outcome of changes in DNA methylation, 
makes DNA methylation a much easier to study phenomenon than mutations. Moreover, changes in 
DNA methylation levels occur in higher frequency than mutations and allow for the detection of more 
tumor cells (Figure 1.6) [97]. And finally, changes in DNA methylation occur earlier in tumorigenesis 
and in general precede mutations (Figure 1.6) [97]. Combined with the reversibility of DNA methylation 
compared to mutations, DNA methylation has a very high potential of diagnostic applicability [97].
Interestingly, during carcinogenesis genome-wide overall hypomethylation is observed (Figure 1.6) [111]. 
This global loss of methylation contributes to tumor development through chromosomal instability as 
result of changes in chromatin structure, reactivation of transposable elements such as LINE-1, which are 
normally silenced by hypermethylation, and loss of imprinting causing expression of genes silenced in 
normal tissue [97]. Besides genome-wide hypomethylation, CpG islands tend to become hypermethylated 
during tumorigenesis which could lead to the repression of specific tumor suppression genes such as the 
DNA-repair gene BRCA1 in breast cancer (Figure 1.6) [112]. 
DNA methylation markers in the clinic
A classic example of a DNA methylation marker in the diagnostic clinical setting is methylation detection 
of the GSTP1 gene. A meta-analysis showed that hypermethylation of the GSTP1 promoter occurs in 82% 
of all prostate cancer and in only 5% of normal prostates. This establishes GSTP1 methylation status as a 







Figure 1.5. DNA methylation is maintained by the family of DNA Methylation Transferases proteins. DNMT1 copies the 
methylation status of the mother strand to the daughter strand during DNA replication, maintaining methylation during inheritance. 
DNMT3a and DNMT3b lead to de novo methylation of previously unmethylated CpG sites. Loss of methylation can be achieved due 
to the activity of a vast collection different compounds or lost by lack of DNMT1 methylation during DNA replication [110].
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The methylation status of the MGMT promoter is being employed as a driver for decision making in 
treatment modalities in neuro-oncology [114]. In glioblastoma patients undergoing chemotherapy 
with alkylating agents, the methylation status of the MGMT promoter predicts a greater response to 
treatment with alkylating agent chemotherapy [115]. The median survival for patients with a methylated 
MGMT promoter was 21.7 months compared to 15.3 months for patients with an unmethylated MGMT 
promoter after treatment [115]. Patients with a hypermethylated MGMT promoter respond especially 
better to treatment with temozolomide than glioblastoma patients with a unmethylated promoter [114]–
[116]. However, the relation between the MGMT promoter methylation status and patient survival is not 
consistent. In addition, the methylation status of MGMT is not persistent with MGMT mRNA levels. Patients 
have been identified with high MGMT expression but a methylated MGMT promoter as well as patients 
with unmethylated MGMT promoters but low MGMT expression [117]. This shows that expression levels 
are not only explained by methylation and other mechanisms are involved. This observation illustrates the 
complexity of mRNA regulation by DNA methylation and raises questions about where the transcriptional 
restricting threshold of DNA methylation clinically lies.
Progress has also been made in the diagnosis of tumor metastasis using DNA methylation markers. In 
breast cancer epigenetic disruption of expression of the cell-adhesion molecule E-cadherin enhances 
the metastatic potential of cancer cells [118]. DNA methylation-mediated down-regulation of adhesion 
molecules has also been observed in the lymph node metastases of melanoma and head and neck cancer 
[119]. More elaborate studies have identified a miRNA methylation signature in primary tumors that is 
associated with lymph node metastasis in HNSCC and other cancers [120]. More recently, using machine 
learning and whole-genome methylation data from The Cancer Genome Atlas, a DNA methylation profile 
has been developed that correctly identified 19 of 20 breast cancer metastases and 29 of 30 colorectal 















Figure 1.6. During carcinogenesis overall levels of methylated cytosines (or 5mC) decline while CpG Islands specifically are 
hypermethylated. These changes in genome wide levels of 5’-methyl-cytosines (5mC) and the hypermethylation of CpG Islands 
in particular occur in higher frequency and earlier in tumorigenesis than the accumulation of DNA mutations. Reproduced with 
permission from [97], Copyright Massachusetts Medical Society.
540123-L-bw-Clausen
Processed on: 16-1-2020 PDF page: 18
CHAPTER 1
18 
In OSCC specifically various studies reported genes that are frequently hypermethylated [122], [123] such 
as CDH1, CDKN2A, MGMT, DAPK1, RARB, and RASSF1, but only a few of these genes are predictive for LN 
metastasis [124], [125]. Several biomarkers reported in other cancers associated with cell migration and 
invasion in vitro [126] and with the presence of nodal metastasis [126], [127] have not been investigated in 
OSCC.
Body fluids can contain whole cells as well as partial DNA fragments originating from tumors. Due to the 
stability of the methylation cytosines, the DNA methylation in these bodily fluids (like saliva, sputum and 
plasma) can be used to determine the methylation status of the whole primary tumor [128]. Even when the 
location of the primary tumor is unknown, the DNA methylation in the body fluids can be used for cancer 
diagnosis. That is because body fluids can carry cell-free DNA that originated from the occult tumor that 
shares genetic aberrations that allow diagnosis as well as guidance in selecting therapeutic modalities 
[129]. For example, in 100% of the patients with squamous cell lung carcinoma hypermethylation of the 
CDKN2A and MGMT was found up to 3 years before clinical diagnosis [130]. Studies like this show the 
application of the detection of DNA methylation in body fluids is a promising new non-invasive early 
diagnostic tool. 
Methylation sensitive endonuclease DNA digestion
Endonucleases are enzymes that cut the DNA in sequence specific locations. Some of these restriction 
enzymes are specific for sequences containing a CpG dinucleotide (reviewed by [131]). For some of these 
enzymes the activity is either blocked or enabled by the presence of a methylation residue on one of 
the nucleotides in the target sequence. Different endonucleases can target the same DNA sequence 
but may have a different DNA methylation sensitivity. This DNA methylation dependent activity can be 
used to measure the methylation status of target sequences of these endonucleases. Downside of these 
techniques is that high amounts of incomplete restriction enzyme digestion of target DNA sequences 
occur, as well as that most of these techniques rely on Southern-blotting which requires a lot of DNA of 
high molecular weight which can be problematic to acquire from tumors
DNA methylation detection
DNA methylation in vivo is maintained during DNA replication by DNA methyltransferases where thenewly 
synthesized DNA strand inherits the DNA methylation pattern of the mother DNA strand throughDNMT1 
activity [108], [109](Figure 1.5). During PCR based methods DNMT1 is absent causing all newlysynthesized 
DNA strands to be complete unmethylated [131]. Therefore, the DNA methylation status ofthe original 
DNA template is obscured and cannot be studied using PCR-based methods. To overcomethis, techniques 
have been developed that translate CpG methylation status first into DNA changes thatare measurable 
by DNA-based methods [131]): methylation-sensitive/insensitive endonuclease digestion[132], affinity 
enrichment [133] and the most widely used bisulfite treatment [134]. 
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Enrichment of methylated DNA
Methylated DNA fragments can be physically separated from non-methylated DNA fragments using 
molecules with an affinity for methylated cytosines. Known methylation-specific molecules include 
antibodies specific for methylated cytosines and proteins that bind methylated DNA such as the 
recombinant human Methyl-CpG-Binding-Domain 2 (MBD2) [135]. By binding methylated DNA fragments 
followed by a precipitation step methylated DNA can be measured in absence of unmethylated DNA [136]
Bisulfite treatment
Sodium Bisulfite is a chemical which has been found to cause the deamination of cytosines to an uracil 
which subsequently results in a thymine during PCR [134]. The principle of this method is that methylated 
cytosines are protected from this chemical conversion while unmethylated cytosines are not. Thus, 
the resulting bisulfite treated DNA sequence differs depending on the target DNA methylation-status 
(Figure 1.7). This process however always requires proper controls to determine the conversion rate of the 
sample DNA. In addition, the loss of high amounts of cytosines during bisulfite conversion results in very 
low complexity DNA as the difference between a high amount of cytosines and thymines are lost which 
makes it harder to distinguish between the resulting sequences. This makes it more difficult to design 
probes and primers specific for a bisulfite treated DNA sequence. However, progress in bioinformatic 
pipelines compensates for some of this lost complexity of sample DNA and thus bisulfite treatment is 
more and more frequently combined with next generation sequencing (NGS) (reviewed by [131]). 
To measure DNA methylation different analysis methods have been developed. In summary there are two 
different kinds of methods for DNA methylation measurements: typing and profiling methods (Figure 
1.8).  Typing technologies are used to assess methylation in a limited amount of genomic locations and is 
generally suited to measure a lot of different samples at the same time for only a few markers (Figure 1.8). 
Figure 1.7. Bisulfite treatment of DNA results in different nucleotide sequences based on the methylation status of the 
cytosines in the target DNA. Unmethylated cytosines are converted into uracil as a result of deamination by the bisulfite treatment. 
PCR amplification of uracil is treated as if these nucleotides were a thymine resulting in adenines in the first amplicon during PCR. 
Methylated cytosines are resistant to this conversion by bisulfite. Amplification of these resistant cytosines results in guanines in 
the first amplicon during PCR where unmethylated DNA treated by bisulfite results in adenines. Picture used from Diagenode with 
permission: https://www.diagenode.com/en/applications/dna-bisulfite-conversion. 
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These techniques rely on prior knowledge or selection of genomic regions. Most of these techniques rely 
on PCR steps such as Methylation Specific PCR, pyrosequencing and Sanger Sequencing.  
Methylation Specific PCR (MS-PCR or MSP) is a variation of conventional PCR performed on bisulfite 
treated DNA. For each locus of interest primer pairs target either the product of unmethylated or 
methylated DNA after bisulfite treatment (Figure 1.7)[138]. During PCR the methylated or unmethylated 
products are amplified separately. Since this technique relies on the difference in target sequence of the 
primers, MS-PCR only interrogates the methylation status of one or two CpG sites in the primer annealing 
sites. A higher amount of CpG sites in the primers would facilitate more unspecific primer binding and 
therefore is not ideal [131], [137]. Best specificity is achieved when the CpG site is located at the 3’ end of 
the forward primers. By combining MSP with fluorescent-labeled probes or a fluorescent dye specific for 
double-stranded DNA, MSP can be measure in a quantitative real-time manner called Quantitative MSP 
(Q-MSP) [139].
Like MSP, pyrosequencing relies on bisulfite treatment of DNA and PCR amplification [140]. However, 
for optimal pyrosequencing analysis unbiased amplification of methylated and unmethylated DNA using 
primers targeting CpG free sequences is needed. After an isolation step of complete amplicons using a 
biotinylated universal primer, up to 80 nucleotides of the amplicon are sequenced using a sequencing 
primer. The DNA sequence is determined using nucleotides with a pyrophosphate group which is released 
during polymerase incorporation of these nucleotides. The amount of released pyrophosphate is directly 
proportional to the number of incorporated nucleotides and is quantified by measuring light released 
by luciferase which is an enzyme driven by the released pyrophosphate. Pyrosequencing determines the 
ratio of methylated and unmethylated cytosines for each CpG residue separately. A disadvantage is that 
pyrosequencing is not always possible when no sufficient CpG-free flanking sequences are available.
Figure 1.8. Examples of different methylation detection techniques. On the Y-axis the number of samples that can be 
simultaneously assessed by a technique are depicted. On the X-axis the amount of CpG sites that can be measured per single run is 
shown. Adapted from [131] with permission.
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COBRA, HPLC and methylation-sensitive restriction-enzymes
Combined bisulfite restriction analysis (COBRA) uses bisulfite treatment and methylation unspecific PCR 
amplification followed by DNA digestion by restriction enzymes [141], [142]. By using restriction enzymes 
that target a CpG site such as the CGCG targeting BstUI, CpG sites can be found that were originally 
methylated in the sample DNA. Because the target sequences recognized by these endonucleases are 
longer and can therefore contain multiple CpG, it can be impossible to target certain CpG sites, that 
are in proximity to other CpG sites, this is specifically problematic when using COBRA. In addition, the 
resolution of COBRA is lower compared to MSP and pyrosequencing when using an endonuclease that 
targets multiple CpG sites simultaneously. 
By using methylation-sensitive and methylation-insensitive endonucleases that target the same CpG 
containing sequence, DNA methylation can be assessed by measuring the size of the DNA fragments 
after digestion using Southern Blotting[143], [144]. Southern blot is a classic technique that is traditionally 
used to semi-quantitatively measure the amount of DNA fragments of specific sizes [145]. The DNA is 
separated based on size using electrophoresis, then the DNA is transferred to a membrane and finally 
hybridized with a labelled DNA probe. 
High performance capillary electrophoresis (HPLC) [146] and High-performance liquid chromatography 
(HPCE) [147] are used to separate DNA molecules by molecular weight, charge, size, hydrophobic potential 
and/or conformation. After the whole DNA sample is digested (for HPLC) or hydrolyzed (for HPCE) into 
single nucleotides, the ratio of normal cytosines and methylated cytosines can be determined. HPCE 
is cheaper and faster than HPLC but is more sensitive to improper DNA isolation due to the chemical 
separation of the nucleotides. 
Methylation Profiling
Methods of broader DNA methylation measurement are called methylation profiling techniques. 
These methods rely less on predetermined regions of interest and allow a more unbiased methylation 
measurement on a much larger scale. Usually using different combinations of NGS with a high number 
of probes or primer, these profiling techniques allow for a more general discovery tool for differences in 
DNA methylation levels. Due to the increased scale and subsequent high-costs these techniques are less 
suited for the testing of extensive patient populations but are a great first step in pinpointing differential 
methylation levels in target groups (reviewed by [137]). 
Whole-Genome Shotgun Bisulfite Sequencing (WGSBS) is basically the whole genome sequencing of bisulfite 
treated DNA. Sample DNA is sheared into small fragments and bisulfite treated (reviewed by [131]). The bisulfite 
converted DNA is then attached to adapters to allow PCR amplification and sequencing [148]. This combination 
of bisulfite treatment and whole genome sequencing gives the highest scale of coverage as well as the highest 
possible resolution of a single CpG site. However, because of the reduced DNA complexity due to bisulfite 
treatment, the mapping of sequencing results to the reference genome becomes difficult. Overall WGBS is very 
expensive to perform and requires very high amounts of DNA input which can be problematic when working 
with precious and low-quality sources of DNA such as formalin-fixed paraffin-embedded (FFPE) samples [131]. 
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Reduced representation bisulfite sequencing (RRBS) combines WGBS with restriction enzymes to enrich 
for CpG high loci [149]. Restriction enzymes are used that cut the DNA at the end of CpG sites which is 
then used as a target site for adapter ligation. Next DNA fragments are size selected, bisulfite treated 
and finally sequenced. RRBS is efficient in capturing the most CpG rich regions such as CpG islands and 
promoters. But RRBS requires very little DNA input. However, regulatory regions with lower CpG content 
such as CpG island shores are missed as well as CpG rich regions that do not contain the target sequence 
of the used endonuclease [131], [137]. 
Methyl-CpG-binding domain sequencing (MethylCap-Seq) is a method of enriching DNA for loci with 
high amounts of methylated CpG sites followed by NGS [150]. The methylated DNA fragments are bound 
by Methyl-CpG-binding domain (MBD) proteins and separated from the unbound DNA fragments and 
subsequently sequenced [136], [151]. Unlike WGBS and RRBS, MethylCap-seq does not require enzymatic 
or bisulfite treatment which removes the limitation to target sequences that contain a particular 
restriction enzyme target site. However, due to the lack of a bisulfite conversion MethylCap-Seq does 
not contain the single base resolution of bisulfite-dependent techniques [137]. The DNA enrichment step 
makes MethylCap-Seq a relative cheap method. Although MethylCap-Seq enrichment is not limited to 
particular CpG rich regions such as CpG islands, DNA fragments need to contain several spatially-close 
methylated CpG sites before MBD binds optimal to methylated DNA fragments. This method is especially 
useful as a discovery tool as it covers methylated fragments of the whole genome. 
Methylated DNA immunoprecipitation (MeDIP) is technique that combines DNA sequencing with 
methylated DNA enrichment comparable to MethylCap-Seq [152]. In contrast to MethylCap-Seq, MeDIP-
Seq uses an antibody for methylated cytosines. While this antibody-dependent approach introduces a 
smaller dependency on a certain threshold of methylated CpG sites that is present in MethylCap-Seq 
[153], MeDIP-Seq cannot distinguish between a methylated cytosine in a CpG dinucleotide and a single 
methylated cytosine [137].
The Infinium 450k is a large-scale microarray containing over 485000 probes [154]. These oligos cover 
up to 96% of all CpG islands and more than 99% of all known promoters [154]. After whole genome 
amplification a DNA sample is bisulfite treated and applied to the microarray chip. These chips contain 
two oligo-probes for each locus, one for the bisulfite converted product of the methylated target 
sequence and one for the bisulfite converted product of the unmethylated DNA target sequence. All 
array oligos end before the cytosine of a CpG site. After the hybridization of target DNA to the array 
oligos, a single nucleotide extension is performed with labelled nucleotides to determine the result of 
the bisulfite-converted nucleotide in the target CpG of the array oligo [155]. Main advantages of the 450k 
microarray are that this technique is relatively cheap, requires little DNA input and contains previously 
identified regions of differential methylation [131], [137]. Compared to the other sequencing techniques 
such as WGBS and RRBS, methylation assessment is limited to the predetermined and designed microarray 
oligo’s [137]. To increase the coverage of the DNA with the Infinium microarray approach an increase in 
the amount of array oligo’s is necessary, which will make the Infinium platform more expensive. 
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MeDIP-CHIP uses methylated DNA enrichment with an antibody specific for methylated cytosines in 
combination with a microarray chip[156]. After isolation of methylated DNA comparable to MeDIP-Seq, 
the DNA is hybridized to a microarray. The chips available for application with MeDIP enrichment are 
limited and contain a maximum of 200000 probes allowing for a very limited view of the methylome [137]. 
In conclusion, the most commonly used techniques are based on restriction enzyme digestion, affinity 
enrichment and bisulfite treatment, combined with microarrays or NGS [157]. The vast majority of loci‐
specific techniques rely on PCR‐based amplification and are easily adapted to commercial platforms. 
These platforms are being employed in many clinical labs with high sensitivity and specificity [158]. More 
specifically, MSP is the most widely used locus‐specific bisulfite‐based DNA methylation analysis and has 
been validated in a large number of clinical samples [137]. To select the most suited technique depends on 
the research questions, the costs, the quality and volume of sample DNA as well as the degree and nature 
of the expected of DNA methylation levels (Figure 1.9) [159]. 
The wide variaty of available techniques reflects the complexity of DNA methylation detection and the 
various stages necessary for making DNA methylation a biomarker suited for the clinic. While, for example, 
most progress in metastasis detection in OSCC has been made with an extensive gene expression 
signature [78], application in the clinic is not feaseble (yet). Employement of the techniques requires 
fresh or frozen tumor samples and are expensive [160].
For the discovery of new methylation marker large datasets of properly defined patient cohorts are 
required. It often takes years to accumulate such datasets for proper retrospective studies. This puts great 
limitations on the available samples. DNA quality and volume are often an important consideration in 
choosing the right technique and differs highly between platforms. 
Recent developments in DNA methylation has elucidated the role of a cytosine methylation intermediate: 
hydroxymethylated cytosines [161], [162]. The role of hydroxymethylation is biologically different from 
methylation and some techniques are incapable of distinguishing between the two modified cytosines 
[137]. 
Additionally, since the relation between hypermethylation of gene promoters and gene expression is not 
always liniar or black and white, some genes require quantitative analysis while in other cases qualitative 
analyses is sufficient. 
To properly establish DNA methylation markers for use in the clinic wide-spread validation by a range of 
institutes is required. To have such broad support, the method used to asses the methylation status of 
the biomarker needs to preferablly be commercially available and applicable by a wide-range of labs [159]. 
Next generation Sequencing based methods are quickly getting more traction as prices of equipment 
and runs drop. However, for the fast, easy and cheap validation of datasets uncovered by NGS, techiniques 
such as MSP will still be required due to their ease and low cost [137], [159]. 
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SCOPE OF THIS THESIS
The goal of this thesis is to generate and explore an Oral Squamous Cell Carcinoma-specific 
Methylome. Using this OSCC-Methylome, new DNA methylation markers will be identified either 
associated with the presence of nodal metastases in pre-treatment primary tumor samples or with the 
presence of tumor cells in saliva during treatment of patients with OSCC. 
In chapter 2 previously reported DNA methylation markers associated with N-status in HNSCC and other 
malignancies were selected from literature searches to investigate the predictive value of these markers 
for the presence of nodal metastases in a cohort of 70 early-stage OSCC selected from a well-established 
database of patients treated in the University Medical Center Groningen between 1997-2008 [163]. For this 
purpose, we compared methylation status detected by MSP of pretreatment biopsies of OSCC patients 
without lymph node metastases (the N0-group) defined as patients without local-regional metastases 
with post-operative follow-up of at least 5 years versus those with lymph node metastases (the N+ group) 
defined by the presence of lymph node metastases at the time of or within 2 years after surgery.
To identify novel DNA methylation tumor markers predictive for the presence of nodal metastases in 
OSCC, we used MethylCap-Seq, an innovative high-resolution technology to uncover DNA-methylation 
in a genome-wide manner. To identify markers that are associated with lymph node status, a methylome 
will be generated from 6 pN0 and 6 pN+ OSCC. Candidate differentially methylated markers will be 
identified and statistically ranked. The highest differentially methylated markers will be validated on a large 
and well-established patient cohort using different typing techniques including MSP, pyrosequencing 
and immunohistochemistry of involved functional genes. In addition, several public datasets for external 
validation and confirmation of the predictive value and biological impact of selected DNA methylation 
markers will be used. 
In chapter 3, the initial construction of the OSCC methylome using MethylCap-seq on the cohort of 
6 pN0 and 6 pN+ OSCC will be described. With this methylome of metastatic OSCC, we aim to identify 
epigenetic markers that are associated with lymph node metastases in OSCC using both statistical 
analyses as well as experimental validation of the epigenetic regulation of lymph node metastasis in 
OSCC. Hypomethylation of the WISP1 gene was further evaluated as an epigenetic marker for pN+ status 
in OSCC.
Because methylation status of genes is related to gene expression, in chapter 4 the MethylCap-seq data 
were combined with a gene expression signature predictive for pN+ status in OSCC and OPSCC [78]. 
Genes with increased methylation status and mRNA down-regulation in pN+ OOSCC will be validated 
using an independent OSCC cohort by both immunohistochemistry and pyrosequencing. Results will be 
confirmed on data retrieved from The Cancer Genome Atlas (TCGA). RAB25 was validated in greater detail 
to validate the clinical value for the detection of lymph node metastases. 
In chapter 5, further data analysis was performed of the MethylCap-Seq data by combining available 
differentially methylated methylation markers with extensive validation of public datasets of TCGA. A new 
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algorithm was developed to select a marker that is down-regulated by hypermethylation in pN+ OSCC 
to identify a biomarker detectable by MSP and suitable as a therapeutic target. The three most relevant 
candidate markers identified by this novel algorithm (KCNAB1, LAMP3 and S100A9) will be further validated 
by pyrosequencing and subsequently immunohistochemistry as potential new markers associated with 
lymph node status.
OSCC are characterized by a relative high frequency of local recurrences of 20-30 % compared to other 
cancers [6][164]. In addition, these local recurrences have a low 30% diagnosis rate at an early localized 
clinical stage [6]. The early detection of tumor cells in saliva of patients with OSCC during follow-up after 
surgery might be of relevance for appropriate therapy-management. To increase the sensitivity of the 
detection of tumor cells in saliva, molecular detection using OSCC specific methylation markers was 
reported previously [165]–[167]. In chapter 6, the combined methylome of all 12 OSCC cases was used to 
identify new OSCC specific methylation markers for the early detection of tumor cells in saliva. For this 
purpose, our OSCC-methylome will be compared to methylation data of two pools of leukocytes and 
other malignancies and healthy tissues as methylation negative controls using the Map of the Human 
Methylome database [168]. New candidate methylation markers will be validated in saliva collected from 
10 OSCC patients. Saliva from five orthognathic surgery patients and five implantology patients served as 
healthy controls. The selected biomarkers will be compared to three reported methylation markers for an 
improved sensitivity and specificity to detect tumor cells in patients with OSCC.
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